Singapore — August 18, 2025 — Leads & Copy — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) addressed recent unusual trading activity and speculation surrounding the company, reaffirming its operational health and commitment to shareholders.
The company’s stock experienced heightened trading volatility over the past week, raising concerns among some shareholders. Cuprina affirmed that it is a fully operational, legally compliant, and mission-driven biotechnology company, focused on advancing its pipeline, expanding access to biotherapeutic solutions, and delivering long-term value to patients, clinicians, and shareholders.
CEO David Quek stated that the company is unaware of any operational reasons for the stock price volatility or any material adverse events. He emphasized that Cuprina is diligently executing its business plan since its IPO earlier this year and highlighted the company’s audited financials, expanding footprint in Asia, and pipeline of regulated medical products.
The company also noted that none of its initial shareholders or founding team members have sold their stock over the past week, underscoring their confidence in Cuprina’s mission, strategy, and long-term growth potential.
Cuprina remains on track with its operational and regulatory milestones, including FDA clearance submission for its medical maggot therapy, expansion of maggot distribution to the Gulf Cooperation Council region, and exploring potential joint ventures and mergers & acquisitions in chronic wound management products.
The company will continue to update shareholders on key developments through timely disclosures and filings.
Investor Relations Contact:
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com
Source: Cuprina Holdings (Cayman) Limited
